Articles related to Oncology, Surgical

Patients whose disease has progressed on osimertinib or other EGFR tyrosine kinase inhibitors (TKIs) without emergent T790M or other targetable alterations can receive platinum-based chemotherapy with or without amivantamab.

Rising levels of EHR work and message volume among oncology physicians are concerning given the role of EHR burden in physician burnout.

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

The emergence of novel agents including BTK degraders, next-generation BCL2 inhibitors, and optimized combination approaches is reshaping the CLL treatment landscape, with multiple trials demonstrating high uMRD rates, improved progression-free survival, and manageable toxicity profiles across different patient populations.

Long-term follow-up data demonstrate a significant overall survival advantage with combination therapy, showing a hazard ratio of 0.54 (95% CI 0.31-0.95) for radiation plus temozolomide versus radiation alone in grade II gliomas.

Family engagement in cancer care extends beyond emotional support, creating tangible impacts on patient outcomes and treatment adherence.